- Home
- VIPS vs IONS Comparison
VIPS vs IONS Comparison
Compare VIPS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIPS
- IONS
- Stock Information
- Founded
- VIPS 2008
- IONS 1989
- Country
- VIPS China
- IONS United States
- Employees
- VIPS N/A
- IONS N/A
- Industry
- VIPS Catalog/Specialty Distribution
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- VIPS Consumer Discretionary
- IONS Health Care
- Exchange
- VIPS Nasdaq
- IONS Nasdaq
- Market Cap
- VIPS 6.8B
- IONS 6.0B
- IPO Year
- VIPS 2012
- IONS 1991
- Fundamental
- Price
- VIPS $13.44
- IONS $31.43
- Analyst Decision
- VIPS Buy
- IONS Buy
- Analyst Count
- VIPS 6
- IONS 18
- Target Price
- VIPS $16.20
- IONS $62.00
- AVG Volume (30 Days)
- VIPS 2.8M
- IONS 1.5M
- Earning Date
- VIPS 02-26-2025
- IONS 02-19-2025
- Dividend Yield
- VIPS 3.19%
- IONS N/A
- EPS Growth
- VIPS 17.49
- IONS N/A
- EPS
- VIPS 2.15
- IONS N/A
- Revenue
- VIPS $15,663,477,774.00
- IONS $803,067,000.00
- Revenue This Year
- VIPS N/A
- IONS N/A
- Revenue Next Year
- VIPS N/A
- IONS $10.85
- P/E Ratio
- VIPS $6.27
- IONS N/A
- Revenue Growth
- VIPS N/A
- IONS 30.57
- 52 Week Low
- VIPS $11.50
- IONS $31.41
- 52 Week High
- VIPS $20.19
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- VIPS 51.79
- IONS 33.19
- Support Level
- VIPS $12.98
- IONS $32.61
- Resistance Level
- VIPS $13.30
- IONS $35.37
- Average True Range (ATR)
- VIPS 0.36
- IONS 1.28
- MACD
- VIPS 0.03
- IONS -0.30
- Stochastic Oscillator
- VIPS 84.26
- IONS 0.36
About VIPS Vipshop Holdings Limited
Vipshop is a Leading Chinese online discount retailer offering branded products at attractive discounts ranging from 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurements, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with over 29,000 global partners as of Dec. 31, 2023. As of March 31, 2024, Eric Ya Shen, chairman and CEO, has 63.1% voting rights and a 30.9% stake while Arthur Xiaobo Hong, vice chairman and COO, has a 17.6% stake. Leading Chinese social media firm and strategic shareholder Tencent also holds an 11.8% interest.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.